343 related articles for article (PubMed ID: 26811602)
1. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.
Akil H; Perraud A; Jauberteau MO; Mathonnet M
World J Gastroenterol; 2016 Jan; 22(2):490-500. PubMed ID: 26811602
[TBL] [Abstract][Full Text] [Related]
2. Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer.
Tanaka K; Okugawa Y; Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Araki T; Uchida K; Mohri Y; Kusunoki M
PLoS One; 2014; 9(5):e96410. PubMed ID: 24801982
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
4. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
5. BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells.
Thomaz A; Jaeger M; Buendia M; Bambini-Junior V; Gregianin LJ; Brunetto AL; Brunetto AT; de Farias CB; Roesler R
J Mol Neurosci; 2016 Jul; 59(3):326-33. PubMed ID: 26614346
[TBL] [Abstract][Full Text] [Related]
6. Neurotrophic tyrosine kinase receptor B/neurotrophin 4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis.
Avcuoglu S; Wygrecka M; Marsh LM; Günther A; Seeger W; Weissmann N; Fink L; Morty RE; Kwapiszewska G
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):768-80. PubMed ID: 21330466
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives.
Tajbakhsh A; Mokhtari-Zaer A; Rezaee M; Afzaljavan F; Rivandi M; Hassanian SM; Ferns GA; Pasdar A; Avan A
J Cell Biochem; 2017 Sep; 118(9):2502-2515. PubMed ID: 28230291
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of BDNF/TrkB and autophagy: a promising therapeutic approach for colorectal cancer.
Mazouffre C; Geyl S; Perraud A; Blondy S; Jauberteau MO; Mathonnet M; Verdier M
J Cell Mol Med; 2017 Oct; 21(10):2610-2622. PubMed ID: 28597984
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
10. Role of Tropomyosin-related kinase B receptor and brain-derived neurotrophic factor in cancer.
Serafim Junior V; Fernandes GMM; Oliveira-Cucolo JG; Pavarino EC; Goloni-Bertollo EM
Cytokine; 2020 Dec; 136():155270. PubMed ID: 32911446
[TBL] [Abstract][Full Text] [Related]
11. Tropomyosin-related kinase B promotes distant metastasis of colorectal cancer through protein kinase B-mediated anoikis suppression and correlates with poor prognosis.
Fan M; Sun J; Wang W; Fan J; Wang L; Zhang X; Yang A; Wang W; Zhang R; Li J
Apoptosis; 2014 May; 19(5):860-70. PubMed ID: 24549576
[TBL] [Abstract][Full Text] [Related]
12. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
[TBL] [Abstract][Full Text] [Related]
13. Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling.
Zou W; Hu X; Jiang L
Curr Cancer Drug Targets; 2020; 20(10):779-788. PubMed ID: 32748747
[TBL] [Abstract][Full Text] [Related]
14. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
16. Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer.
Kawamoto M; Onishi H; Ozono K; Yamasaki A; Imaizumi A; Kamakura S; Nakano K; Oda Y; Sumimoto H; Nakamura M
Oncotarget; 2017 May; 8(22):36211-36224. PubMed ID: 28423707
[TBL] [Abstract][Full Text] [Related]
17. TrkB as a therapeutic target for ovarian cancer.
Siu MK; Wong OG; Cheung AN
Expert Opin Ther Targets; 2009 Oct; 13(10):1169-78. PubMed ID: 19694498
[TBL] [Abstract][Full Text] [Related]
18. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
[TBL] [Abstract][Full Text] [Related]
19. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
